Stocktoria
Stoke Therapeutics, Inc. STOK
Stoke Therapeutics, Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $184.4M | $36.6M | $8.8M | $12.4M | — | — | — | — |
| R&D expense | $137.9M | $89.1M | $82.2M | $77.8M | $54.2M | $32.2M | $23.8M | $8.4M |
| SG&A expense | $67.1M | $48.8M | — | — | — | — | — | — |
| Operating income | -$20.6M | -$101.4M | -$114.8M | -$104.4M | -$86.1M | -$53.0M | -$35.7M | -$12.8M |
| Interest expense | $9,000 | $26,000 | $49,000 | — | — | — | — | — |
| Income tax | $0 | — | — | — | — | — | — | — |
| Net income | -$6.9M | -$89.0M | -$104.7M | -$101.1M | -$85.8M | -$52.2M | -$32.3M | -$12.5M |
| EPS (diluted) | $-0.12 | $-1.65 | $-2.38 | $-2.60 | $-2.34 | — | — | — |
| Operating cash flow | $45.6M | -$86.9M | -$81.1M | -$31.9M | -$66.9M | -$42.2M | -$31.1M | -$11.0M |
| Free cash flow | $44.9M | -$87.1M | -$82.7M | -$35.8M | -$68.1M | -$43.3M | -$32.7M | -$11.9M |
| Cash & equivalents | $84.2M | $128.0M | $191.4M | $113.6M | $144.9M | $287.3M | $222.5M | $105.4M |
| Total assets | $418.4M | $271.6M | $228.3M | $256.1M | $238.9M | $297.9M | $228.8M | $107.5M |
| Total liabilities | $66.0M | $42.5M | $68.8M | $71.2M | $21.1M | $11.8M | $4.3M | $2.5M |
| Shareholders' equity | $352.5M | $229.0M | $159.6M | $184.8M | $217.8M | $286.1M | $224.4M | $105.1M |
Growth · year-over-year · Revenue CAGR 145.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | +404.5% | +316.3% | -29.2% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.